Voyageur Pharmaceuticals Clarifies Distribution Agreement Terms

Voyageur Pharmaceuticals ( (TSE:VM) ) just unveiled an update.

Voyageur Pharmaceuticals Ltd. has clarified the terms of a previously announced distribution and wholesaling agreement for its SmoothX 2% contrast medium, intended for use in abdominal CT diagnostic examinations in Latin America. The agreement, initially announced with a sales commitment of USD $1.9 million over three years, does not obligate the distributor to purchase any products, and no orders have been placed or fulfilled to date. This clarification impacts Voyageur’s market positioning by emphasizing the nature of the agreement and its reliance on future regulatory approvals and sales commencement targeted for the second half of 2025.

More about Voyageur Pharmaceuticals

Voyageur Pharmaceuticals Ltd., a Canadian public company listed on the TSXV under the symbol VM, is focused on developing barium and iodine Active Pharmaceutical Ingredients. The company aims to offer cost-effective imaging contrast agents and seeks to vertically integrate the barium and iodine contrast markets. Voyageur has developed five barium contrast products that have received Health Canada licenses and plans to partner with established third-party GMP pharmaceutical manufacturers in Canada to validate its products.

YTD Price Performance: 35.90%

Average Trading Volume: 32,499

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $16.67M

See more data about VM stock on TipRanks’ Stock Analysis page.